

Sokrates Stein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/949763/publications.pdf>

Version: 2024-02-01

37
papers

2,808
citations

257450

24
h-index

345221

36
g-index

37
all docs

37
docs citations

37
times ranked

5077
citing authors

#	ARTICLE	IF	CITATIONS
1	Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. <i>Journal of Clinical Investigation</i> , 2011, 121, 2693-2708.	8.2	464
2	A SIRT7-Dependent Acetylation Switch of GABP ² Controls Mitochondrial Function. <i>Cell Metabolism</i> , 2014, 20, 856-869.	16.2	214
3	Protective roles of SIRT1 in atherosclerosis. <i>Cell Cycle</i> , 2011, 10, 640-647.	2.6	211
4	SIRT1 decreases Lox-1-mediated foam cell formation in atherogenesis. <i>European Heart Journal</i> , 2010, 31, 2301-2309.	2.2	189
5	TGR5 reduces macrophage migration through mTOR-induced C/EBP ² differential translation. <i>Journal of Clinical Investigation</i> , 2014, 124, 5424-5436.	8.2	166
6	SIRT1 reduces endothelial activation without affecting vascular function in ApoE ^{-/-} mice. <i>Aging</i> , 2010, 2, 353-360.	3.1	132
7	Hyperactive S6K1 Mediates Oxidative Stress and Endothelial Dysfunction in Aging: Inhibition by Resveratrol. <i>PLoS ONE</i> , 2011, 6, e19237.	2.5	131
8	Mouse Models for Atherosclerosis Researchâ€”Which Is My Line?. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 46.	2.4	118
9	The Sirt1 activator SRT3025 provides atheroprotection in ApoE ^{-/-} mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression. <i>European Heart Journal</i> , 2015, 36, 51-59.	2.2	117
10	Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease. <i>Journal of Hepatology</i> , 2017, 66, 132-141.	3.7	115
11	Sirt1 inhibition promotes in vivo arterial thrombosis and tissue factor expression in stimulated cells. <i>Cardiovascular Research</i> , 2011, 89, 464-472.	3.8	97
12	Heart-Infiltrating Proliferin-1 ⁺ /CD133 ⁺ Progenitor Cells Represent the Cellular Source of Transforming Growth Factor β -Mediated Cardiac Fibrosis in Experimental Autoimmune Myocarditis. <i>Circulation Research</i> , 2009, 105, 462-470.	4.5	90
13	Endothelial overexpression of LOX-1 increases plaque formation and promotes atherosclerosis in vivo. <i>European Heart Journal</i> , 2014, 35, 2839-2848.	2.2	82
14	SUMOylation-Dependent LRH-1/PROX1 Interaction Promotes Atherosclerosis by Decreasing Hepatic Reverse Cholesterol Transport. <i>Cell Metabolism</i> , 2014, 20, 603-613.	16.2	73
15	Neutrophils in cardiovascular disease. <i>European Heart Journal</i> , 2017, 38, 1702-1704.	2.2	62
16	SIRT1 â€” An Anti-Inflammatory Pathway at the Crossroads Between Metabolic Disease and Atherosclerosis. <i>Current Vascular Pharmacology</i> , 2012, 10, 693-696.	1.7	59
17	Molecular basis for the regulation of the nuclear receptor LRH-1. <i>Current Opinion in Cell Biology</i> , 2015, 33, 26-34.	5.4	58
18	LRH-1-dependent programming of mitochondrial glutamine processing drives liver cancer. <i>Genes and Development</i> , 2016, 30, 1255-1260.	5.9	56

#	ARTICLE	IF	CITATIONS
19	Macrophage NCOR1 protects from atherosclerosis by repressing a pro-atherogenic PPAR β signature. <i>European Heart Journal</i> , 2020, 41, 995-1005.	2.2	56
20	Impaired SUMOylation of nuclear receptor LRH-1 promotes nonalcoholic fatty liver disease. <i>Journal of Clinical Investigation</i> , 2017, 127, 583-592.	8.2	50
21	LRH-1 mediates anti-inflammatory and antifungal phenotype of IL-13-activated macrophages through the PPAR β ligand synthesis. <i>Nature Communications</i> , 2015, 6, 6801.	12.8	46
22	Fas cell surface death receptor controls hepatic lipid metabolism by regulating mitochondrial function. <i>Nature Communications</i> , 2017, 8, 480.	12.8	40
23	ApoE $\Delta\Delta$ /PGC-1 $\Delta\Delta$ Mice Display Reduced IL-18 Levels and Do Not Develop Enhanced Atherosclerosis. <i>PLoS ONE</i> , 2010, 5, e13539.	2.5	29
24	Sirt6 deletion in bone marrow-derived cells increases atherosclerosis – Central role of macrophage scavenger receptor 1. <i>Journal of Molecular and Cellular Cardiology</i> , 2020, 139, 24-32.	1.9	26
25	Multifactorial Regulation of a Hox Target Gene. <i>PLoS Genetics</i> , 2009, 5, e1000412.	3.5	23
26	Implications of NAD ⁺ boosters in translational medicine. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13334.	3.4	20
27	Deletion of fibroblast activation protein provides atheroprotection. <i>Cardiovascular Research</i> , 2021, 117, 1060-1069.	3.8	20
28	Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease – From Bench to Bedside. <i>Frontiers in Physiology</i> , 2021, 12, 755060.	2.8	13
29	The NO-donor MPC-1011 stimulates angiogenesis and arteriogenesis and improves hindlimb ischemia via a cGMP-dependent pathway involving VEGF and SDF-1 β . <i>Atherosclerosis</i> , 2020, 304, 30-38.	0.8	12
30	Brain-derived neurotrophic factor Val66Met polymorphism in depression and thrombosis: SIRT1 as a possible mediator. <i>European Heart Journal</i> , 2017, 38, ehv692.	2.2	10
31	Role of the Nuclear Receptor Corepressor 1 (NCOR1) in Atherosclerosis and Associated Immunometabolic Diseases. <i>Frontiers in Immunology</i> , 2020, 11, 569358.	4.8	9
32	Profibrotic potential of Prominin-1+epithelial progenitor cells in pulmonary fibrosis. <i>Respiratory Research</i> , 2011, 12, 126.	3.6	7
33	A Dual Role of CD4+ T Cells in Adipose Tissue?. <i>Circulation Research</i> , 2009, 104, 928-930.	4.5	6
34	JCAD: from systems genetics identification to the experimental validation of a coronary artery disease risk locus. <i>European Heart Journal</i> , 2019, 40, 2409-2412.	2.2	4
35	Protective role of the co-stimulator CD27 receptor and regulatory T cells in early atherogenesis. <i>European Heart Journal</i> , 2017, 38, 3600-3602.	2.2	2
36	CardioPulse: Translational research in cardiovascular disease. <i>European Heart Journal</i> , 2016, 37, 1091-2.	2.2	1

#	ARTICLE	IF	CITATIONS
37	Adipose tissue macrophage polarization in cardiovascular disease. European Journal of Preventive Cardiology, 2018, 25, 325-327.	1.8	0